Supplementary Table 2. Characteristics of primary T-ALL patient samples. No matched diagnosis sample was available for the relapsed sample. Mutations subtypes % Patient ID/ thawing Patient at: Age Sex Risk group response fusion after deletion deletion deletion deletion deletion deletion deletion viability amplification deletion Outcome HOX11 HOX11L NOXA9 Cell SIL-TAL1 Prednisolone MLLT3 MTAP MYB Immuno-phenotype CASP8AP2 CDKN2A CDKN2B NUP214-ABL1 SIL-TAL PTEN LEF T-MR-09 Diagnosis 1 2 2 1 Y 8.0 male 8 P R 90 T-MR-04 Diagnosis 1 1 2 Y 14.3 male 8 G CCR 90 T-HR-04 Diagnosis 1 1 2 Y 15.0 male 7 P CCR 90 T-VHR-26 Diagnosis 1 1 1 3.8 female 9 P R 90 T-R-18 Relapse Y 6.7 male 9 80 T-HR-12 Diagnosis 1 1 2 2 8.4 male 9 P CCR 90
Supplementary Table 2. Characteristics of primary T-ALL patient samples. No matched diagnosis sample was available for the relapsed sample. Mutations subtypes Patient ID/ Risk group Patient at: SIL-TAL1 HOX11 HOX11L NOXA9 Age Sex Immuno-phenotype Prednisolone response Outcome Cell viability after thawing % SIL-TAL deletion LEF deletion CASP8AP2 deletion MLLT3 deletion MTAP deletion CDKN2A deletion CDKN2B deletion PTEN deletion MYB amplification NUP214-ABL1 fusion T-MR-09 Diagnosis 1 2 2 1 Y 8.0 male 8 P R 90 T-MR-04 Diagnosis 1 1 2 Y 14.3 male 8 G CCR 90 T-HR-04 Diagnosis 1 1 2 Y 15.0 male 7 P CCR 90 T-VHR-26 Diagnosis 1 1 1 3.8 female 9 P R 90 T-R-18 Relapse Y 6.7 male 9 80 T-HR-12 Diagnosis 1 1 2 2 8.4 male 9 P CCR 90